title: From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City.
abstract: This study examined potential facilitators and barriers to pre-exposure prophylaxis (PrEP) use and their association with PrEP acceptability and motivations for adherence among 184 MSM and transgender women living in New York City. Participants were presented with educational information about PrEP and completed a computerized survey. Overall, 55.4% of participants reported willingness to take PrEP. The most highly endorsed barriers to PrEP use were health concerns, including both long-term impacts and short-term side effects, questions about PrEP's impact on future drug resistance, and concerns that PrEP does not provide complete protection against HIV. The most highly endorsed facilitator was free access to PrEP, followed by access to support services such as regular HIV testing, sexual health care/monitoring, and access to one-on-one counseling. Participants of color rated both barriers and facilitators as more important than their White counterparts. In multivariate models, barrier and facilitator scores significantly predicted not only PrEP acceptability, but also motivation for PrEP adherence among those who were likely to use PrEP. PrEP implementation programs should consider addressing these barriers and facilitators in protocol and policy development. Findings underscore the importance of support services, such as sexual health counseling, to the success of PrEP as a prevention strategy.
authors.affiliation: Department of Psychology, Hunter College of the City University of New York, New York, New York 10065, USA. sarit.golub@hunter.cuny.edu
authors.forename: Sarit A
authors.initials: SA
authors.lastname: Golub
authors.forename: Kristi E
authors.initials: KE
authors.lastname: Gamarel
authors.forename: H Jonathon
authors.initials: HJ
authors.lastname: Rendina
authors.forename: Anthony
authors.initials: A
authors.lastname: Surace
authors.forename: Corina L
authors.initials: CL
authors.lastname: Lelutiu-Weinberger
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D007722:Health Knowledge, Attitudes, Practice; D006297:Health Services Accessibility; D018451:Homosexuality, Male / Q000523:psychology*; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009042:Motivation; D009519:New York City; D010342:Patient Acceptance of Health Care / Q000523:psychology*; D012044:Regression Analysis; D012307:Risk Factors; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D063106:Transgender Persons / Q000523:psychology*; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents
references.citation: N Engl J Med. 2012 Aug 2;367(5):423-34
references.pmid: 22784038
references.citation: PLoS One. 2012;7(3):e33119
references.pmid: 22470438
references.citation: J Soc Issues. 2005 Mar;61(1):109-26
references.pmid: 17073026
references.citation: AIDS Patient Care STDS. 2012 Jul;26(7):395-405
references.pmid: 22694239
references.citation: J Acquir Immune Defic Syndr. 2010 Sep;55(1):8-13
references.pmid: 21423876
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8
references.pmid: 21270743
references.citation: J Womens Health (Larchmt). 2010 Apr;19(4):791-8
references.pmid: 20210540
references.citation: AIDS Patient Care STDS. 2012 Apr;26(4):222-33
references.pmid: 22404427
references.citation: PLoS One. 2012;7(11):e50061
references.pmid: 23166819
references.citation: J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):241-7
references.pmid: 18340656
references.citation: Lancet. 2012 Jul 28;380(9839):341-8
references.pmid: 22819656
references.citation: PLoS Clin Trials. 2007 May 25;2(5):e27
references.pmid: 17525796
references.citation: AIDS Care. 2008 Jan;20(1):106-15
references.pmid: 18278621
references.citation: AIDS Patient Care STDS. 2010 Nov;24(11):689-91
references.pmid: 20863247
references.citation: AIDS Care. 2011 Sep;23(9):1136-45
references.pmid: 21476147
references.citation: N Engl J Med. 2010 Dec 30;363(27):2587-99
references.pmid: 21091279
references.citation: N Engl J Med. 2008 Apr 10;358(15):1560-71
references.pmid: 18337596
references.citation: Curr HIV/AIDS Rep. 2010 Nov;7(4):201-9
references.pmid: 20809218
references.citation: AIDS Behav. 2012 Jul;16(5):1243-59
references.pmid: 22460228
references.citation: J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):77-83
references.pmid: 19295337
references.citation: Prev Med. 2004 Feb;38(2):209-18
references.pmid: 14715214
references.citation: PLoS One. 2012;7(7):e40603
references.pmid: 22792384
references.citation: AIDS. 2012 Aug 24;26(13):1585-98
references.pmid: 22507927
references.citation: Cancer. 2009 Jun 1;115(11):2553-61
references.pmid: 19296516
references.citation: AIDS Patient Care STDS. 2011 Feb;25(2):63-71
references.pmid: 21284497
references.citation: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007189
references.pmid: 19160329
references.citation: Health Psychol. 2012 May;31(3):269-77
references.pmid: 22059617
references.citation: Science. 2008 Feb 22;319(5866):1026-7
references.pmid: 18292313
references.citation: N Engl J Med. 2012 Aug 2;367(5):399-410
references.pmid: 22784037
references.citation: J Acquir Immune Defic Syndr. 2010 Aug;54(5):548-55
references.pmid: 20512046
references.citation: AIDS Patient Care STDS. 2012 Feb;26(2):87-94
references.pmid: 22149764
references.citation: Clin Infect Dis. 2010 Sep 1;51(5):496-505
references.pmid: 20673002
references.citation: J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8
references.pmid: 22267018
references.citation: Curr Opin HIV AIDS. 2012 Nov;7(6):514-9
references.pmid: 22964886